Ratings Medica S.p.A.

Equities

MDC

IT0005460149

Market Closed - Borsa Italiana Other stock markets 11:44:59 2024-05-10 am EDT			5-day change	1st Jan Change
26.8 ^EUR	0.00%		+1.52%	+72.90%

Apr. 29	Donaldson Agrees to Acquire 49% Stake in Medica	MT
Apr. 26	Response Plus Unit Closes Prometheus Medical Acquisition	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Sales forecast by analysts have been recently revised upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 56.42 times its estimated earnings per share for the ongoing year.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
MEDICA S.P.A.	+72.90%	122M	-
MODERNA, INC.	+17.96%	44.96B	B-
LONZA GROUP AG	+48.77%	41.85B	A
IQVIA HOLDINGS INC.	+1.17%	42.65B	B
CELLTRION, INC.	-4.27%	29.04B	C
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B	B
BIO-TECHNE CORPORATION	+4.86%	12.75B	B+
MEDPACE HOLDINGS, INC.	+27.29%	12.06B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes